MCC-18-MULTI-25-PMC (ESR-17-13115): Phase 2 Investigation of MEDI4736 (Durvalumab) and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

Grants and Contracts Details

StatusActive
Effective start/end date5/7/1911/2/24

Funding

  • AstraZeneca Pharmaceuticals AB: $123,004.00